Vorasidenib (Voranigo, Servier Laboratories) is indicated for 'the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and paediatric patients 12 years and older, who are not in need of immediate chemotherapy or radiotherapy following surgical intervention'.
The dosage schedule is available in the summary of product characteristics for vorasidenib.
The list price of a 30-tablet pack of vorasidenib is £15,000 for 40-mg tablets and £7,500 for 10-mg tablets (excluding VAT; company submission).
The company has a commercial arrangement. This makes vorasidenib available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, Servier Laboratories did not disclose its Carbon Reduction Plan for UK carbon emissions.